Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer
Open accessThe DOI matches its Crossref record.
Abstract
Phosphatidylinositol-3 kinase (PI3K) pathway is one of the most frequently activated pathogenic signaling cascades in human malignancies. PI3K is genetically mutated or overexpressed in a wide variety of cancers including ovarian, breast, prostate, gastric, colorectal, glioblastoma, endometrial and brain cancers. Studies are still ongoing to find more efficient and selective PI3K inhibitors or dual PI3K inhibitors to overcome the resistance to the current inhibitors. This review will focus on the three main classes of PI3K inhibitors with efficacious antitumor activity which are: isoform-selective PI3K inhibitors, dual pan-Class I PI3K/m-TOR inhibitors, and pan-Class I PI3K inhibitors without significant m-TOR activity. Isoform-selective PI3K inhibitors are classified into four classes IA, IB, II, and III. Moreover, SAR among each class, together with the biological activity will be discussed. In addition, the new scopes for the design of novel candidates to overcome emerging resistance will be highlighted as well.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
Mishra, R., Patel, H., Alanazi, S., Kilroy, M. K., & Garrett, J. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073464 · Cited by 281
Targeting SHIP1 and SHIP2 in Cancer
Pedicone, C., Meyer, S. T., Chisholm, J. D., & Kerr, W. G. (2021) · Cancers · doi:10.3390/cancers13040890 · Cited by 42
Recent advances of tanshinone in regulating autophagy for medicinal research
Wu, S., Zhao, K., Wang, J., Liu, N., Nie, K., Qi, L., & Xia, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1059360 · Cited by 32
Focused Libraries for Epigenetic Drug Discovery: The Importance of Isosteres: Miniperspective
Green, A. I., & Burslem, G. M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00592 · Cited by 21
Metadata
- Authors
- Elmenier, F. M., Lasheen, D. S., & Abouzid, K. A. M.
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 183
- Pages
- 111718
- ISSN
- 0223-5234 (ISSN-L)
- OpenAlex
- W2974238339
- Cited by
- 120
- References
- 0
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer. https://app.cochat.ai/papers/10.1016/j.ejmech.2019.111718
- The paper
- Elmenier, F. M., Lasheen, D. S., & Abouzid, K. A. M. (2019). Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer. European Journal of Medicinal Chemistry. https://doi.org/10.1016/j.ejmech.2019.111718
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.